| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007337565 |
| P356 | DOI | 10.1038/NG.632 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/ng.632 |
| P698 | PubMed publication ID | 20639878 |
| P5875 | ResearchGate publication ID | 45272237 |
| P2093 | author name string | Fan Yang | |
| Joanne Meyer | |||
| Timothy M Wright | |||
| Jonathan B Singer | |||
| Elisabeth Leroy | |||
| Xiaojun Zhao | |||
| Lloyd Klickstein | |||
| Steve Lewitzky | |||
| Charles A Paulding | |||
| P2860 | cites work | Idiosyncratic drug hepatotoxicity | Q36148442 |
| Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis | Q36274544 | ||
| Idiosyncratic drug reactions: current understanding | Q36551883 | ||
| Pharmacological interaction of drugs with immune receptors: the p-i concept. | Q36639657 | ||
| Drug hepatotoxicity from a regulatory perspective | Q36920984 | ||
| The genetics of multiple sclerosis: SNPs to pathways to pathogenesis | Q37187340 | ||
| Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis | Q61781514 | ||
| Hy's law: predicting serious hepatotoxicity | Q82907987 | ||
| PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial | Q28211411 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial | Q28211435 | ||
| Genetic variations in HLA-B region and hypersensitivity reactions to abacavir | Q28214097 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| HLA association of amoxicillin-clavulanate--induced hepatitis | Q28375211 | ||
| HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin | Q29417159 | ||
| Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir | Q34117815 | ||
| Drug-related hepatotoxicity | Q34495071 | ||
| Lumiracoxib in the management of osteoarthritis and acute pain | Q34657320 | ||
| HLA-B*5701 screening for hypersensitivity to abacavir | Q34747145 | ||
| Co-amoxiclav jaundice: clinical and histological features and HLA class II association. | Q35361803 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 711-714 | |
| P577 | publication date | 2010-07-18 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury | |
| P478 | volume | 42 |
| Q84183100 | A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis |
| Q36798284 | A PheWAS approach in studying HLA-DRB1*1501. |
| Q36729997 | A case of acute liver failure due to etodolac |
| Q38085220 | A review of pharmacogenetics of adverse drug reactions in elderly people |
| Q38836848 | A web resource for mining HLA associations with adverse drug reactions: HLA-ADR |
| Q44858073 | Accuracy of SNPs to predict risk of HLA alleles associated with drug-induced hypersensitivity events across racial groups |
| Q48296572 | Acute liver failure induced by idiosyncratic reaction to drugs: Challenges in diagnosis and therapy |
| Q47715776 | Antituberculosis Drug-Induced Adverse Events in the Liver, Kidneys, and Blood: Clinical Profiles and Pharmacogenetic Predictors. |
| Q37862739 | Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity |
| Q39043874 | Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study |
| Q86077113 | Avoiding idiosyncratic DILI: two is better than one |
| Q57163738 | Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation |
| Q38194173 | Biomarkers: refining diagnosis and expediting drug development - reality, aspiration and the role of open innovation |
| Q36669589 | Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen |
| Q42354312 | CSH guidelines for the diagnosis and treatment of drug-induced liver injury |
| Q36542583 | Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis |
| Q26749054 | Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury |
| Q37872195 | Case definition and phenotype standardization in drug-induced liver injury. |
| Q34417032 | Causality assessment for suspected DILI during clinical phases of drug development |
| Q57318857 | Celecoxib for rheumatoid arthritis |
| Q37926590 | Central role of mitochondria in drug-induced liver injury |
| Q50699986 | Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells. |
| Q53497512 | Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. |
| Q36171663 | Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database |
| Q38431150 | Clinical association between pharmacogenomics and adverse drug reactions |
| Q90256099 | Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis |
| Q36762374 | Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01. |
| Q27005695 | Contributions of nonhematopoietic cells and mediators to immune responses: implications for immunotoxicology |
| Q34996898 | Current progress in pharmacogenetics. |
| Q38271339 | Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis |
| Q36885006 | DILI: New Insights into Diagnosis and Management |
| Q46213703 | Dealing with stress |
| Q85225089 | Design, synthesis and in vivo anti-inflammatory activities of 2,4-diaryl-5-4H-imidazolone derivatives |
| Q50624617 | Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. |
| Q33730146 | Developing pharmacogenetic evidence throughout clinical development |
| Q41889353 | Digging up the human genome: current progress in deciphering adverse drug reactions. |
| Q55564369 | Drug Induced Hypersensitivity and the HLA Complex. |
| Q39037269 | Drug metabolism and liver disease: a drug-gene-environment interaction |
| Q26767296 | Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States |
| Q47781069 | Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status |
| Q33755165 | Drug-Induced Liver Injury: Cascade of Events Leading to Cell Death, Apoptosis or Necrosis |
| Q52346835 | Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention. |
| Q30241050 | Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management |
| Q37748005 | Drug-induced liver injury: Do we know everything? |
| Q37867695 | Drug-induced liver injury: a summary of recent advances. |
| Q30235089 | Drug-induced liver injury: recent advances in diagnosis and risk assessment |
| Q35210890 | Drug-induced liver injury: the dawn of biomarkers? |
| Q26800980 | Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response. |
| Q91876299 | Exosomal Transport of Hepatocyte-Derived Drug-Modified Proteins to the Immune System |
| Q28477582 | Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study |
| Q27692095 | Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy. |
| Q41389082 | Genetic Factors Influencing Drug-Induced Liver Injury: Do They Have a Role in Prevention and Diagnosis? |
| Q37931275 | Genetic association studies in drug-induced liver injury |
| Q36811351 | Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? |
| Q38207944 | Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review |
| Q39178438 | Genetics of primary sclerosing cholangitis and pathophysiological implications |
| Q39158128 | Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation |
| Q49931634 | Genome-wide and Phenome-wide Approaches to Understand Variable Drug Actions in Electronic Health Records. |
| Q37806616 | Genome-wide association studies and genetic risk assessment of liver diseases |
| Q34170453 | Genome-wide association study identifies susceptibility loci for IgA nephropathy |
| Q33582530 | Genotyping for severe drug hypersensitivity |
| Q47553722 | HLA Association with Drug-Induced Adverse Reactions. |
| Q54193741 | HLA DQB1 alleles are related with nonalcoholic fatty liver disease. |
| Q37963995 | HLA alleles and drug hypersensitivity reactions |
| Q28534593 | HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity |
| Q38037649 | HLA and pharmacogenetics of drug hypersensitivity. |
| Q89556419 | HLA associations with infliximab-induced liver injury |
| Q93091889 | HLA-B*35:01 Allele Is a Potential Biomarker for Predicting Polygonum multiflorum-Induced Liver Injury in Humans |
| Q40346340 | HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer |
| Q37193472 | HLA-DQ B1*0201 and A1*0102 Alleles Are Not Responsible for Antituberculosis Drug-Induced Hepatotoxicity Risk in Spanish Population. |
| Q42362078 | HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity |
| Q38949927 | HLADR: a database system for enhancing the discovery of biomarkers for predicting human leukocyte antigen-mediated idiosyncratic adverse drug reactions. |
| Q47320133 | HLAs: Key regulators of T-cell-mediated drug hypersensitivity. |
| Q30244369 | Hepatotoxicity induced by coxibs: how concerned should we be? |
| Q38542198 | Hepatotoxicity of New Oral Anticoagulants (NOACs). |
| Q37832129 | Hepatotoxicity related to antirheumatic drugs |
| Q30238992 | Human leucocyte antigen-adverse drug reaction associations: from a perspective of ethnicity. |
| Q53361002 | Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. |
| Q38285818 | Human leukocyte antigen genetic risk factors of drug-induced liver toxicology |
| Q37590883 | Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays |
| Q26824391 | Idiosyncratic adverse drug reactions: current concepts |
| Q38145274 | Idiosyncratic drug-induced liver injury: an update on the 2007 overview |
| Q26787099 | Impact of New Genomic Technologies on Understanding Adverse Drug Reactions |
| Q34316771 | In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers |
| Q43505002 | Inhibition of immune tolerance unmasks drug-induced allergic hepatitis |
| Q37961088 | Integrative genomics strategies to elucidate the complexity of drug response |
| Q38127461 | Intrahepatic cholestasis in common chronic liver diseases. |
| Q38024403 | Investigative safety science as a competitive advantage for Pharma |
| Q38045377 | Latest advances in predicting DILI in human subjects: focus on biomarkers |
| Q36796350 | Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs |
| Q41641046 | Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience |
| Q46514701 | Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites |
| Q36848555 | Major Histocompatibility Class II Pathway Is Not Required for the Development of Nonalcoholic Fatty Liver Disease in Mice |
| Q91362516 | Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models |
| Q44230800 | Managing the risk of drug-induced liver injury |
| Q29248263 | Mechanism of isoniazid‐induced hepatotoxicity: then and now |
| Q57302639 | Mechanisms of Adverse Drug Reactions |
| Q36479455 | Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications |
| Q26998806 | Mechanisms of drug-induced liver injury |
| Q34169362 | Mechanisms of drug-induced liver injury: from bedside to bench |
| Q64241600 | Mechanisms of hypersensitivity reactions induced by drugs |
| Q26781801 | MicroRNAs in Drug-induced Liver Injury |
| Q40454552 | Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. |
| Q38107545 | Molecular insights from dysregulation of the thiazide-sensitive WNK/SPAK/NCC pathway in the kidney: Gordon syndrome and thiazide-induced hyponatraemia. |
| Q26800973 | New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunity |
| Q26800976 | New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity |
| Q91959902 | Next-Generation DILI Biomarkers: Prioritization of Biomarkers for Qualification and Best Practices for Biospecimen Collection in Drug Development |
| Q92377619 | Novel circulating- and imaging-based biomarkers to enhance the mechanistic understanding of human drug-induced liver injury |
| Q64269386 | Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity |
| Q34417013 | Ongoing challenges in pharmacovigilance |
| Q27690772 | Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives |
| Q37578868 | Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies |
| Q42592319 | Personalized medicine in rheumatoid arthritis: miles to go before we sleep |
| Q38756015 | Personalized medicine: Genetic risk prediction of drug response |
| Q42124676 | Pervasive haplotypic variation in the spliceo-transcriptome of the human major histocompatibility complex |
| Q38391340 | Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice |
| Q38933314 | Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review. |
| Q38050316 | Pharmacogenetics of nonsteroidal anti-inflammatory drugs |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q47357309 | Pharmacogenomic Biomarkers for Improved Drug Therapy-Recent Progress and Future Developments |
| Q37658586 | Pharmacogenomics and patient care: one size does not fit all. |
| Q37284234 | Pharmacogenomics in clinical practice and drug development |
| Q27015820 | Pharmacogenomics of adverse drug reactions |
| Q38036150 | Pharmacogenomics of adverse drug reactions: implementing personalized medicine |
| Q30400366 | Pharmacogenomics of off-target adverse drug reactions |
| Q34342305 | Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury |
| Q34994860 | Pharmacogenomics: will the promise be fulfilled? |
| Q38771635 | Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans |
| Q40092387 | Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia |
| Q34348246 | Polymorphism in glutamate cysteine ligase catalytic subunit (GCLC) is associated with sulfamethoxazole-induced hypersensitivity in HIV/AIDS patients |
| Q38269781 | Practical approaches to resolving reactive metabolite liabilities in early discovery |
| Q38031096 | Predictive genetic testing for drug-induced liver injury: considerations of clinical utility |
| Q63241927 | Preempting and preventing drug-induced liver injury |
| Q28083100 | Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity |
| Q37506497 | Promise of pharmacogenomics for drug discovery, treatment and prevention of Parkinson's disease. A perspective |
| Q57177177 | Proteomics Analysis of Monocyte-Derived Hepatocyte-Like Cells Identifies Integrin Beta 3 as a Specific Biomarker for Drug-Induced Liver Injury by Diclofenac |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q36252524 | Relating human genetic variation to variation in drug responses |
| Q33658002 | Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial |
| Q37974923 | Role of immune reactions in drug-induced liver injury (DILI). |
| Q36702588 | Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice |
| Q41927200 | Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. |
| Q91841581 | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions |
| Q60678518 | Similar Maximum Systemic but not Local Cyclooxygenase-2 Inhibition by 50 mg Lumiracoxib and 90 mg Etoricoxib: A Randomized Controlled Trial in Healthy Subjects |
| Q35085772 | Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles |
| Q34971993 | T cell-mediated hypersensitivity reactions to drugs |
| Q36766056 | Testing for drug hypersensitivity syndromes |
| Q28080256 | The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity |
| Q26764776 | The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative |
| Q26772999 | The Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role? |
| Q44075475 | The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study. |
| Q27023725 | The challenges, advantages and future of phenome-wide association studies |
| Q38651282 | The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. |
| Q47571376 | The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future |
| Q38369889 | The emerging science of precision medicine and pharmacogenomics for Parkinson's disease |
| Q38848580 | The transformation in biomarker detection and management of drug-induced liver injury |
| Q37925027 | Thiazide-induced hyponatraemia: epidemiology and clues to pathogenesis |
| Q28478443 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps) |
| Q51109085 | Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients. |
| Q35681250 | Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology |
| Q26779078 | Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury |
| Q47446885 | miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model. |
Search more.